Search Articles
SEATTLE – Shareholders say directors of Dendreon Corp. dumped $9.5 million of their own shares at prices inflated by false statements about its major product, an expensive cancer drug called Provenge, and that Dendreon’s market cap sank 72% in a day when the truth came out.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.